普鲁士蓝
坏死性下垂
纳米医学
串扰
化学
医学
癌症研究
纳米颗粒
药理学
线粒体
转录组
纳米技术
活性氧
细胞生物学
电压依赖性阴离子通道
作者
Lingling Xu,Lixian Jiang,Rongrong Wu,Hongyu Yan,Bo Li,Xiaojun Cai,Yuanyi Zheng
标识
DOI:10.1038/s41467-026-70012-2
摘要
The extensive crosstalk among pyroptosis, apoptosis, and necroptosis limits the efficacy of therapies targeting only one pathway. Here, we show that Prussian blue (PB) nanoparticles act as multi-target PANoptosis inhibitors by binding key PANoptosome components including RIPK1, ZBP1, and AIM2 through multimodal interactions, thereby concurrently suppressing pyroptosis, apoptosis, and necroptosis in myocardial ischemia-reperfusion injury (MIRI). Platelet membrane-coated PB nanoparticles (PB@PM) exhibit enhanced cardiac targeting and efficiently alleviate MIRI-induced cardiac dysfunction, adverse ventricular remodeling, and cardiomyocyte hypertrophy. Mechanistically, PB@PM disrupt PANoptosome assembly, scavenge reactive oxygen species, improve mitochondrial function, and restore immune-inflammatory homeostasis. By integrating single nucleus transcriptomics of human heart samples, molecular dynamics simulations, transcriptomics, medical imaging, and molecular validation, we systematically decipher the therapeutic mechanisms of PB-based PANoptosis inhibition. This study establishes an integrative multi-omics framework for exploring PANoptosis in cardiovascular diseases and provides a promising nanotherapeutic strategy for MIRI treatment.
科研通智能强力驱动
Strongly Powered by AbleSci AI